[A19-44] Fremanezumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V
Last updated 15.08.2019
Project no.:
A19-44
Commission:
Commission awarded on 15.05.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Migraine prophylaxis in adult patients with at least 4 migraine days per month
Added benefit not proven due to a lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-82 | Fremanezumab (migraine) - Addendum to Commission A19-44 | Commission completed |
Federal Joint Committee (G-BA)
2019-11-07 A G-BA decision was published.